Drugs Made In America Acquisition Corp. Ordinary Shares

Day range

$10.88 – $10.89

Open

$10.88

Prev close

$10.88

Volume

9.19K

Market cap

$264.01M

Shares out

24.28M

P/E

32.33

P/S

—

P/B

-35.66

P/FCF

—

ROE

-110.3%

ROA

5.6%

Debt/Equity

-0.05

Div yield

0.00%

As of Oct 23, 2026

• Merger agreementOct 21, 2026

  On October 13, 2026, Drugs Made In America Acquisition Corp. and Power Analytics Global Corp. entered into Amendment No. 1 to their Amended and Restated Definitive Merger Agreement dated as of September 8, 2026. The Amendment was approved by the boards of directors of both parties.

• Merger agreementSep 14, 2026

  On September 8, 2026, following approval by the Company's board of directors, the Company and PAGC entered into an Amended and Restated Definitive Merger Agreement (the "A&R Merger Agreement"), which amends and restates the Existing Agreement in its entirety.

• Merger agreementJul 20, 2026

  On July 14, 2026, the Boards of Directors of the Company and PAGC approved a third amendment to the Merger Agreement... The Merger Agreement, as amended, provides for a business combination pursuant to which PAGC will merge with and into the Company (or a wholly-owned subsidiary of the Company, as may be mutually agreed by the parties), with the surviving entity continuing as the Company's combined operating business following the closing (the "Merger").

• Merger agreementMay 5, 2026

  On April 29, 2026, Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the "Company" or "DMAA"), entered into a Definitive Merger Agreement (the "Merger Agreement") with Power Analytics Global Corp, a Delaware corporation engaged in the business of artificial intelligence, advanced analytics and quantum-resistant security solutions ("PAGC"). The Merger Agreement provides for a business combination pursuant to which PAGC will merge with and into the Company (or a wholly-owned subsidiary of the Company, as may be mutually agreed by the parties), with the surviving entity continuing as the Company's combined operating business following the closing (the "Merger").

• Charter amendmentMay 1, 2026

  A proposal, by special resolution, to amend the Company's Second Amended and Restated Memorandum and Articles of Association (the "Existing Charter") by adopting an amendment to the Existing Charter in the form set forth in Annex A to the Proxy Statement (the "Extension Amendment") which reflects the extension of the date by which the Company must consummate a business combination (the "Combination Period") up to twelve (12) times from April 29, 2026 (the "Termination Date") to April 29, 2027.

Days to cover

101.0

Short interest

89.79K

Avg volume

889

As of Sep 30, 2026 · reported to FINRA twice monthly.